2020
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research 2020, 26: 3928-3935. PMID: 32601075, PMCID: PMC8792803, DOI: 10.1158/1078-0432.ccr-20-0953.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemotherapy, AdjuvantCystadenocarcinoma, SerousCytoreduction Surgical ProceduresDrug Administration ScheduleEndometrial NeoplasmsEndometriumFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelProgression-Free SurvivalReceptor, ErbB-2Survival AnalysisTrastuzumabConceptsProgression-free survivalRandomized phase II trialPhase II trialOverall survivalHER2/neuStage IIICarboplatin-paclitaxelII trialRecurrent diseaseControl armSurvival analysisRecurrent uterine serous carcinomaCarboplatin/paclitaxelUterine serous carcinomaOverall survival analysisEvaluable patientsEligible patientsPrimary endpointSecondary endpointsEndometrial cancerAggressive variantSerous carcinomaPrimary treatmentSurvival medianPatientsLaparoscopic Posterior Versus Lateral Transversus Abdominis Plane Block in Gynecology
Benabou K, Kim S, Tierney CH, Messom JE, Kyriakides TC, Kashani SM, Silasi DA, Azodi M, Seifi F. Laparoscopic Posterior Versus Lateral Transversus Abdominis Plane Block in Gynecology. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2020, 24: e2020.00032. PMID: 32831540, PMCID: PMC7434395, DOI: 10.4293/jsls.2020.00032.Peer-Reviewed Original ResearchConceptsTransversus abdominis plane blockPostoperative pain scoresLaparoscopic gynecologic surgeryTAP blockPain scoresGynecologic surgeryPlane blockLateral transversus abdominis plane blockLateral TAP blockPosterior TAP blockTAP block groupBody mass indexDemographic characteristicsPre-operative diagnosisLength of stayRegional anesthesia techniquesDifferent operative proceduresInvasive gynecologic surgeryLaparoscopic posteriorNarcotic intakeOpioid consumptionAnesthesiologists classificationNarcotic usagePostoperative painAnalgesic effect
2015
Comparison of Lymphedema Incidence Between 2 Lymphadenectomy Techniques in Patients With Uterine Cancer Undergoing Robotic Staging
Menderes G, Azodi M, Schwartz P, Silasi DA. Comparison of Lymphedema Incidence Between 2 Lymphadenectomy Techniques in Patients With Uterine Cancer Undergoing Robotic Staging. International Journal Of Gynecological Cancer 2015, 25: 160-165. PMID: 25386859, DOI: 10.1097/igc.0000000000000308.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedAged, 80 and overCarcinoma, EndometrioidCarcinosarcomaConnecticutCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansIncidenceLymph Node ExcisionLymph NodesLymphatic MetastasisLymphedemaMiddle AgedNeoplasm StagingPara-Aortic BodiesPelvic NeoplasmsPrognosisRoboticsUterine NeoplasmsConceptsSelective pelvic lymphadenectomyExternal iliac lymph nodesLower extremity lymphedemaStandard pelvic lymphadenectomyIliac lymph nodesPelvic lymphadenectomyLymph nodesLymphadenectomy groupRobotic stagingExtremity lymphedemaUterine cancerPara-aortic lymph nodesPelvic lymphadenectomy groupIncidence of lymphedemaMean operative timePelvic lymph nodesBody mass indexPostoperative hospitalizationSelective lymphadenectomyConsecutive patientsEndometrial cancerEndometrioid adenocarcinomaLymphedema incidenceMass indexOperative time
2014
Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging
Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA. Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging. International Journal Of Gynecological Cancer 2014, 24: 1118-1125. PMID: 24927247, DOI: 10.1097/igc.0000000000000156.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedAged, 80 and overBody Mass IndexCarcinosarcomaCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansHysterectomyLymph Node ExcisionLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesRoboticsSurvival RateConceptsBody mass indexRecurrence-free survivalRobotic-assisted stagingEndometrial cancerRecurrence rateDisease recurrenceMass indexMean postoperative hospitalizationLymph node countMean operative timeLong-term outcomesNonendometrioid cancersMorbid obesityPostoperative hospitalizationMetastatic diseaseNonendometrioid histologyObese patientsOverall survivalConsecutive patientsOperative outcomesHistologic subtypeOperative timeSurgical outcomesEndometrioid carcinomaMean age
2012
Robotic-Assisted Laparoscopic Hysterectomy: Outcomes in Obese and Morbidly Obese Patients
Gallo T, Kashani S, Patel DA, Elsahwi K, Silasi DA, Azodi M. Robotic-Assisted Laparoscopic Hysterectomy: Outcomes in Obese and Morbidly Obese Patients. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2012, 16: 421-427. PMID: 23318068, PMCID: PMC3535794, DOI: 10.4293/108680812x13462882735890.Peer-Reviewed Original ResearchConceptsBody mass indexObese patientsLaparoscopic hysterectomyBMI groupsRobotic-assisted laparoscopic hysterectomyCommunity teaching hospitalLength of stayAssisted Laparoscopic HysterectomyNonobese patientsPerioperative outcomesPatient characteristicsPatient demographicsBlood lossOperative outcomesSurgical indicationsOperative timeRetrospective reviewMass indexRobotic hysterectomySurgical outcomesMalignant conditionsTeaching hospitalCase of womenHysterectomyPatients